<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632358</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP311X2201</org_study_id>
    <secondary_id>2012-000857-29</secondary_id>
    <nct_id>NCT01632358</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Crossover Study to Assess Safety and Tolerability, Pharmacokinetics, and Explore Pharmacodynamics of TAP311 in Patients With Mixed Dyslipidaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients
      with dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>Summary statistics on number of patients with total adverse events, serious adverse events and death will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TAP311: The observed maximum plasma concentration following drug administration at steady state (Cmax,ss)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Day 1 - Cmax, Day 14 - Cmaxss, from the plasma concentration-time data. Each parameters will be one outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TAP311: The time to reach the maximum concentration after drug administration at steady state(Tmax, ss)</measure>
    <time_frame>Day 1 and Day 14 profile</time_frame>
    <description>The time to reach the maximum concentration after drug administration at steady state(Tmax, ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TAP311: The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1</time_frame>
    <description>The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TAP311: The Racc ratio from the plasma concentration-time data</measure>
    <time_frame>Day 14</time_frame>
    <description>The Racc ratio from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TAP311: The AUCtau, from the plasma concentration-time data</measure>
    <time_frame>Day 14</time_frame>
    <description>The AUCtau, from the plasma concentration-time data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>TAP311 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive TAP311 capsule orally once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of TAP311 capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to TAP311 capsule, once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP311 capsules</intervention_name>
    <arm_group_label>TAP311 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo of TAP311 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 to 80 years (inclusive) of age.

          -  Patients are not treated for dyslipidemia with medications other than HMG-CoA
             reductase inhibitors (statins) for at least 4 weeks prior to Day 1. Patients should be
             on stable doses of current medications, if any, for at least 3 months to be eligible.

          -  Patients must weigh at least 50 kg to participate in the study, and must have a body
             mass index (BMI) within the range of 18 - 40 kg/m2.

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrollment

          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes

          -  Use of lipid modifying agents (e.g. fenofibrate, niacin, omega-3 fatty acids, etc.)
             other than statins will exclude subjects.

          -  Pregnant or nursing (lactating) women

          -  Diabetic patients whose plasma glucose is not well controlled by stable diabetic
             treatment for at least 3 months

          -  Heavy smokers (smoke more than 10 cigarettes a day routinely and who cannot refrain
             from smoking during the study).

          -  Women of child-bearing potential (WOCBP) can be included but must use highly effective
             contraception

          -  Significant illness within two (2) weeks prior to initial dosing

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Lithuania</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2012</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

